Inhibition of lipid oxidation increases glucose metabolism and enhances 2-deoxy-2-[¹⁸F]fluoro-D-glucose uptake in prostate cancer mouse xenografts by Schlaepfer, Isabel R. et al.
Mol Imaging Biol (2014)
DOI: 10.1007/s11307-014-0814-4
* The Author(s), 2014. This article is published with open access at Springerlink.com
RESEARCH ARTICLE
Inhibition of Lipid Oxidation Increases Glucose
Metabolism and Enhances 2-Deoxy-2-
[18F]Fluoro-D-Glucose Uptake in Prostate
Cancer Mouse Xenografts
Isabel R. Schlaepfer,1 L. Michael Glodé,1 Carolyn A. Hitz,2 Colton T. Pac,3
Kristen E. Boyle,4 Paul Maroni,5 Gagan Deep,6 Rajesh Agarwal,6 Scott M. Lucia,7
Scott D. Cramer,3 Natalie J. Serkova,8 Robert H. Eckel2
1Division of Medical Oncology, Genitourinary Cancer Program, University of Colorado School of Medicine, MS 8117 12801 E. 17th Ave,
Room L18-8101D, Aurora, CO, 80045, USA
2Division of Endocrinology Metabolism and Diabetes, University of Colorado Denver, Aurora, CO, 80045, USA
3Department of Pharmacology, University of Colorado Denver, Aurora, CO, 80045, USA
4Department of Pediatrics, University of Colorado Denver, Aurora, CO, 80045, USA
5Department of Surgery, University of Colorado Denver, Aurora, CO, 80045, USA
6School of Pharmacy, University of Colorado Denver, Aurora, CO, 80045, USA
7Department of Pathology, University of Colorado Denver, Aurora, CO, 80045, USA
8Department of Anesthesiology, University of Colorado Denver, Aurora, CO, 80045, USA
Abstract
Purpose: Prostate cancer (PCa) is the second most common cause of cancer-related death
among men in the United States. Due to the lipid-driven metabolic phenotype of PCa, imaging
with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is suboptimal, since tumors tend to have low
avidity for glucose.
Procedures: We have used the fat oxidation inhibitor etomoxir (2-[6-(4-chlorophenoxy)-
hexyl]oxirane-2-carboxylate) that targets carnitine-palmitoyl-transferase-1 (CPT-1) to increase
glucose uptake in PCa cell lines. Small hairpin RNA specific for CPT1A was used to confirm the
glycolytic switch induced by etomoxir in vitro. Systemic etomoxir treatment was used to enhance
[18F]FDG-positron emission tomography ([18F]FDG-PET) imaging in PCa xenograft mouse
models in 24 h.
Results: PCa cells significantly oxidize more of circulating fatty acids than benign cells via CPT-1
enzyme, and blocking this lipid oxidation resulted in activation of the Warburg effect and
enhanced [18F]FDG signal in PCa mouse models.
Conclusions: Inhibition of lipid oxidation plays a major role in elevating glucose metabolism of
PCa cells, with potential for imaging enhancement that could also be extended to other cancers.
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Introduction
Prostate cancer is the most common malignancy in menand the second leading cause of cancer in the USA. The
interplay of genetic and metabolic events that lead to
prostate cancer remain unclear, but recent studies increas-
ingly recognize the role of highly elevated lipid metabolism
in prostate cancer (PCa) research [1]. The metabolism of
PCa is unique in comparison to other cancers because it is
not dependent on the strong aerobic glycolysis typical of
solid tumors, also known as the Warburg effect. In contrast,
PCa cells preferentially shunt glucose carbons towards
lipogenesis [2] and rely more on beta-oxidation to satisfy
their energetic needs [3]. This reduced dependence on
glucose is likely the basis of a decreased positron emission
tomography (PET) signal with 2-deoxy-2-[18F]fluoro-D-
glucose ([18F]FDG) tracers, especially in localized tumors
[4]. However, the ability of PCa tumors to perform aerobic
glycolysis remains intact, as new magnetic resonance
spectroscopic imaging techniques indicate that C-13
hyperpolarized pyruvate delivered to mouse prostate or
PCa patients is readily transformed to lactate [5, 6].
The exact mechanisms of glucose uptake and lipid
metabolism in PCa cells remain unknown. Increased glucose
uptake is only observed in advanced metastatic PCa, while
lipid turnover can be observed in both primary and advanced
PCa, likely accounting for the differences in detection of
prostate cancers by PET-glucose imaging techniques [7]. In
fact, studies have shown that [18F]FDG is readily taken up
by cultured metastatic PCa cells and this uptake is strongly
increased with hypoxia, a known activator of glycolysis in
cancer cells [8].
Clinically safe lipid oxidation inhibitors such as etomoxir
could be used to alter lipid metabolism and aerobic glycolysis
in PCa cells. Etomoxir is an irreversible inhibitor of the long-
chain fatty acid transporter and has been used in the treatment
of heart failure as a metabolic inducer for the glycolytic switch
[9]. It works by inhibiting carnitine-palmitoyl-transferase-1
(CPT-1), an enzyme anchored in the outer membrane of the
mitochondria. Etomoxir blocks the entry of long-chain fatty
acids into the mitochondria for oxidation, forcing cells to utilize
oxidation of glucose for energy.
Blocking CPT-1 activity with etomoxir produces thera-
peutic benefits in the treatment of heart failure by shifting
the energy supply from fatty acids to glucose [10]. Etomoxir
also shows this therapeutic effect in PCa tumors [11],
suggesting that the metabolic switch between lipids and
glucose is also operating in PCa cells [12]. We hypothesized
that this shift towards glucose could be also happening in
lipid-utilizing cells (like PCa cells) to increase radio-labeled
glucose uptake and enhance [18F]FDG uptake in vivo. In this
study, we examined the metabolic effects of blocking lipid
oxidation in PCa cells in vitro as well as in vivo, using
mouse xenograft models and the transgenic adenocarcinoma
of mouse prostate (TRAMP) model for [18F]FDG-PET
imaging analysis.
Materials and Methods
Cell Culture and Drug Treatments
Cells were obtained from the University of Colorado Cancer Center
and were authenticated by Single Tandem Repeat analysis
(University of Colorado Cancer Center). Cells were passaged in
RPMI (except VCaP cells in DMEM) (Invitrogen) containing 5 %
fetal bovine Serum supplemented with amino acids and insulin
(Hyclone). Human primary prostate-derived cells were isolated
(IRB protocol: 00–812) and expanded in keratinocyte medium as
previously described [13]. PC3-LUC cells were from Applied
Biological Materials ABM and grown in Prigrow IV media
(Applied Biological Materials ABM-TM004) plus 10 % FBS and
1 % P/S. Etomoxir-HCl (Sigma) was dissolved into a 10 mM stock
solution in water and stored at −20 °C.
Lipid Oxidation
Cells were plated in 12-well plates and grown to 70 % confluence
in their respective growth media conditions and with 150 uM
etomoxir at the indicated times. At the time of the assay, 1 mM
carnitine, 100 uM bovine serum albumin (BSA)-conjugated fatty
acids (Sigma) and C-14 labeled fatty acids (1 uCi/ml; PerkinElmer)
and fresh media were added to the cells for 3 h. Entrapment of the
generated [14C]CO2 was done by transferring the media to a sealed
dual-chamber plate and injecting percloric acid to release the
14CO2, which was trapped in a NaOH solution in the adjacent well
as previously described [14]. The radioactivity in the NaOH
solution (containing the trapped [14C]CO2) was measured by
scintillation counting (Beckman). Cells were washed twice with
PBS, harvested in 200 ul of 0.05 % SDS lysis buffer and stored at
−80 ° C for subsequent determination of protein concentration.
Glucose Uptake
Basal glucose uptakes were determined as previously reported for
human cells in vitro [15]. Briefly, cells (105) in six-well plates were
incubated in Krebs–Ringer bicarbonate-HEPES (KRBH) buffer
(130 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 1.3 mM MgSO4,
25 mM HEPES, pH 7.4) containing 1 % fatty acid-free BSA
(Sigma-Aldrich), 2-deoxy-D-glucose (0.5 mM; Sigma-Aldrich), and
2-deoxy-D-[1,2-3H]glucose (GE Healthcare) for 20 min at 37 °C.
The cells were washed with ice-cold KRBH buffer, harvested in
800 μl of lysis buffer (Pierce Biotechnology) and then added to
scintillation vials containing 5 ml of scintillation fluid. Radioactive
counts were determined with a scintillation counter (LS6500;
Beckman Coulter). Counts were converted to moles of glucose
taken up and normalized to the protein concentration of the lysates.
NMR Analysis of 1-[13C]Glucose Uptake
and 3-[13C]-actate Export In Vitro
VCaP cells were incubated with 5 mM of 1-[13C]glucose
(Cambridge Isotope Laboratories) and with vehicle or etomoxir
drug for 24 h. Incubation media (9 ml) were collected and
lyophilized overnight. Lyophilized media were re-dissolved in
I.R. Schlaepfer et al.: Lipid Oxidation Blockade Increases Prostate Tumor Glucose Uptake
0.5 ml of deuterium oxide, and the samples were analyzed by
quantitative 1H- and 13C-nuclear magnetic resonance (NMR)
spectroscopy [16]
RT-PCR and shRNA Constructs Targeting CPT1A
cDNA was amplified by real-time polymerase chain reaction (PCR)
using SYBR green (Applied Biosystems) detection. Specific
primers are listed in Electronic supplementary material (ESM)
Table 1. TRCN0000036279 and TRCN0000036281 CPT1A small
hairpin RNAs (shRNAs) s and the non-targeting control SHC002
were purchased from Functional Genomics Core, Boulder, Colora-
do. Lentiviral transduction and selection were performed according
to Sigma's MISSION protocol but using lentiviral packing plasmids
pCMV-R8.74psPAX2 and VSV-G/pMD2.G and transfection re-
agent TransIT-LT1 (Mirius) as described [11].
Immunoblots
Protein extracts (20 μg) were separated on a 7.5 % SDS-PAGE gel
and transferred to nitrocellulose (Invitrogen) membranes for
Western blot analysis. All antibodies were from Cell-Signaling.
Band signals were visualized with ECL (Pierce).
Xenograft Production and TRAMP Mice
Male athymic nude mice, 4–6 weeks old (Harlan Laboratories),
were housed in the University of Colorado Center for Comparative
Medicine. Subcutaneous xenografts were generated by injecting
human VCaP cells in the flank of mice as described [11].
Approximately, 2 million cells were used for each injection. When
tumors were palpable they were used for scans. Treatment was
carried out with a single intraperitoneal injection of etomoxir
(20 mg/kg) immediately after the basal PET scan. After 24 h the
mice were subjected to a second PET scan. Mice were euthanized
when no longer radioactive. For orthotopic xenografts, PC3-LUC
cells (PC3 cells expressing the luciferase reporter) were injected in
the right anterior lobe of prostates and monitored by biolumines-
cence with intraperitoneal injection of luciferin (IVIS imaging
systems, Perkin Elmer). TRAMP transgenic mice were purchased
from JAX® Mice at 6–8 weeks of age. All procedures were carried
out under an approved University of Colorado Animal Care
protocol.
[18F]FDG-PET, Magnetic Resonance Imaging
Single-position, whole-body imaging was performed using a
Siemens Inveon PET scanner at the University of Colorado Cancer
Center Animal Imaging Core. FDG-PET was performed before
treatment (basal) and after 24 h of systemic etomoxir (20 mg/kg)
treatment. Mice were fasted for 6 h before [18F]FDG injection, and
blood glucose levels was assessed prior to the [18F]FDG injection
(all animals had G80 mg/ml of circulating glucose). Approximately
250 μCi of [18F]FDG, obtained through University of Colorado
Hospital (PetNet solutions), was administered by tail vein injection
to conscious animals (the precise dose was assessed by measuring
the syringe before and after the injection) [17]. Animals were
maintained in temperature-controlled cages for 1 h to allow for
[18F]FDG uptake in tumors. Under isoflurane anesthesia (2.5 %),
animals were placed on a warm pad (m2m Imaging), and a 10-min
emission scan was acquired. [18F]FDG uptake in mouse tumor
xenografts, orthototpic tumors, as well as control tissues (prostate,
muscle, heart, and brown fat) was done by analyzing the micro-
PET images with the ASIProVM (Concorde Microsystems)
software. Regions of interest were drawn with the trace command
around the tumors on scan slices, and the total activity of all tumor
slices was summed. Total activity was divided by the time-
corrected dose-delivered [time-corrected dose=dose injected×
exp(−0.006317 x t)], where t is the time between the injection
and scan time, and it is shown as the fold change of the baseline
scan of each respective tumor. Representative images were
generated using the Siemens Inveon Research Workplace software
(v3.1.2). Conventional proton-density weighted MRI was used to
assess TRAMP prostate size growth as described [18].
Statistical Analysis
Analysis was done with SPSSv21 (IBM) using t tests and ANOVA
Tukey’s post hoc analysis. PG0.05 was considered significant. All
tests were two-sided. Data represent mean±SD.
Results
CPT1A-Mediated Blockade of Beta-Oxidation
Increases Glucose Uptake in Prostate Cells
Fig. 1a shows the effect of etomoxir on the production of
[14C]CO2 after incubation of the cells with [
14C]oleate over
2 days. Note the increased oxidation rate in PCa cells
(LNCaP, VCaP, and PC3) compared with the non-cancer
controls (BPH-1 and WPMY-1 cells) at 0 h. VCaP cells
oxidized the most oleic acid. Fig. 1b shows the effect of
etomoxir on lipid oxidation rate with [14C]palmitate. In the
absence of etomoxir treatment, LNCaP cells showed the
highest rate of palmitic oxidation. Using RT-PCR, we
observed that PCa cells have abundant expression of the
CPT1A (liver) isoform, underscoring capacity of these
PCa cells to oxidize fat; see Fig. 1c. VCaP cells showed
the highest expression of CPT1A, which is parallel to the
increased oleic acid oxidation capacity (Fig. 1a). Fig. 1d
shows CPT1A protein expression of the cell lines
examined.
Since etomoxir targets the CPT-1 enzyme [19, 20], we
used shRNAs to decrease CPT1A expression in LNCaP cells
and mimic the pharmacological effects of etomoxir. We
obtained two clones with specific knockdown (KD) of
CPT1A, as shown in Fig. 2a, which surprisingly responded
to 24 h etomoxir treatment by increasing CPT1A protein
expression, likely reflecting a compensatory response. The
36279 and 36281 CPT1A KD clones decreased palmitate
oxidation by 60 % and 25 %, respectively, when compared
with control-transfected cells; see Fig. 2b. These effects
were further decreased by addition of etomoxir in clone
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36281 but not in 39279, suggesting maximal inhibition of
beta-oxidation in the 36279 clone, which had the lowest
CPT1A expression.
Since etomoxir was designed as a drug that increases
glucose uptake by blocking lipid utilization [21], we
examined the effects of etomoxir on glucose uptake in the
LNCaP CPT1A KD clones. Both CPT1A KD clones showed
significant increase of basal glucose uptake (~57 %,
PG0.001) compared with control the clone, plus additional
increased glucose uptake after etomoxir treatment for 6 h;
see Fig. 2c.
We next examined prostate biopsy-derived primary cells.
Etomoxir treatment (6 h) resulted in significant increase in
glucose uptake (1.76-fold, PG0.05) in patient-derived
benign prostate cells, but the effect was stronger in the
adjacent tumor-derived cells (2.7-fold, PG0.01); see Fig. 3a.
We then extended these studies to PCa (LNCaP, VCaP,
PC3) and benign (BPH-1, WPMY-1) cell lines. Overall, PCa
cell lines showed progressive increase in glucose uptake
compared with no treatment (0 h), ANOVA, PG0.01; see
Fig. 3b. Interestingly, benign BPH-1 and WPMY-1 did not
show a significant increase in 2DG uptake with etomoxir; in
fact, BPH-1 cells showed a slight decrease by 24 h.
In cancer cells, one of the most common avenues for
glucose metabolism is its conversion into lactate, which
results in media acidification. To quantify the induction of
aerobic glycolysis, we obtained 13C-glucose spectra of
VCaP cells exposed to etomoxir for 24 h (ESM Fig. 1).
Table 1 shows the quantification of the extracellular
concentrations of C-13-labeled glucose and lactate metabo-
lites from the 1-[13C]glucose in the media of the VCaP cells.
There was a twofold increase in 3-[13C]lactate export in the
etomoxir-treated cells, concomitant with a significant in-
crease in glucose uptake. These results strongly support the
concept that the inhibition of lipid oxidation in PCa cells
further induces the Warburg effect in PCa.
Systemic Beta-Oxidation Blockade Increases
[18F]FDG Uptake in PCa Mouse Models
To investigate if this flare of enhanced glucose uptake effect
could also be happening in vivo, we used three mouse
models of PCa: subcutaneous xenografts with VCaP cells
(n=16), orthotopic xenografts with PC3-Luciferase cells (n=
4), and genetic TRAMP mouse models (n=6). All mice were
treated with 20 mg/kg of etomoxir by IP injection after a
basal PET scan and subjected to another PET scan after
24 h. Fig. 4a shows representative images of the before
(basal) and after scans of the subcutaneous xenografts,
showing increased glucose uptake (white9orange). Green
color reflects the lowest uptake. Notice that the tumor (white
arrow) is barely visible in the basal scan but becomes visible
in 24 h with treatment. Fig. 4b shows the significant fold
change difference (P=0.03) in normalized glucose uptake
values (NUV) between the etomoxir and water-treated
subcutaneous tumors. Student’s paired t test of the before
and after measurements for each etomoxir-treated mouse
also showed a significant fold change in uptake (1.4±0.3,
Fig. 1 Lipid oxidation is abundant in prostate cancer cells
and interrupted by etomoxir. a) The effect of etomoxir
(150 μM) on the [14C]oleic acid oxidation rate at the indicated
times. Benign cells are BPH-1 and WPMY-1. a Benign (n=6)
vs. PCa (n=9) without treatment, ttest—P=0.004. b Effect of
4 h treatment on oleate oxidation in PCa cells. ANOVA
PG0.001, post hoc Tukey’s: LNCaP (PG0.001), VCaP
(PG0.001), PC3 (P=0.002). b) Effect of etomoxir on [14C]pal-
mitate oxidation. c Benign (n=6) vs. PCa (n=9) with no
treatment, ttest—P=0.006. d Effect of 4-h treatment on
palmitate oxidation in PCa cells. ANOVA PG0.001, post hoc
Tukey’s: LNCaP (P=0.001), VCaP (P=0.001), PC3 (PG0.001).
c) CPT1 isoform expression in PCa cells and BPH-1 benign
line. Post hoc tests, *P≤0.03 compared with BPH-1. #P≤
0.002 compared with BPH-1. d) CPT1A Western blot of cell
lines examined. αTUB=tubulin loading control.
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P=0.001). When we examined the NUV fold change in the
mouse prostate tissue, the [18F]FDG uptake was minimal in
the healthy prostate gland, close to the background activity.
Etomoxir did not produce significant changes over basal
scan (0.96±0.07). Mice treated with vehicle (water) showed
the same result, (1.0±0.04). However, as expected, signif-
icant NUV fold changes were observed in leg muscle (1.32±
1.2, PG0.01), subscapular brown adipose tissue or BAT
(1.43±1.3, PG0.001) and heart (2.52±0.75, P=0.02) com-
pared with basal scans. Additionally, to make the study more
relevant for clinical imaging purposes, tumor-to-tissue total
activity ratios were also calculated. As shown in Table 2, we
observed a significant tumor/prostate ratio increase after
systemic etomoxir (P≤0.03). The tumor/muscle ratios with
etomoxir were also significantly increased, reflecting the
systemic effect of etomoxir in muscle tissue.
After the scans, animals were sacrificed, and tumor
lysates were prepared. As expected from increased glucose
metabolism, Hexokinase-2 (HK2), p-mTOR, and p-
S6Kinase were increased in the etomoxir-treated tumors;
see Fig. 4c. No significant changes in GLUT1 glucose
transporter were observed after 24 h of etomoxir treatment;
data are not shown. Ex vivo incubation of xenograft
fragments (~20 mg) with [14C]palmitate and etomoxir
resulted in more than tenfold decrease in [14C]CO2 produc-
tion, as shown in Fig. 4d, underscoring the strong sensitivity
of VCaP-based xenografts to lipid burning inhibitors.
Fig. 5a shows representative images of mice with
orthotopic xenografts of PC3-luciferase cells. The PC3-
LUC cells were surgically implanted in the right lobe of the
mouse prostates. Mice in the images developed metastases in
the abdomen that could be seen by bioluminescence. Only
mice that showed luciferase expression were used for the
PET scans. We observed a 2.7±1.40-fold increase in NUV
after etomoxir treatments for 24 h (P=0.04). We also
performed PET scans in TRAMP mice, which uniformly
and spontaneously develop autochthonous (orthotopic) pros-
tate tumors following the onset of puberty. Interestingly, like
the human PCa tumors, the TRAMP tumors do not show
increased expression of glucose transporters, which likely
explains low [18F]FDG uptake [22]. Fig. 5b shows images of
24-week-old TRAMP mice, an interval at which growth of
PCa is well documented [18]. The tumor behind the bladder
(arrow) was significantly stronger after etomoxir treatment,
and growth of prostate tissue into the seminal vesicles was
observed in PET and MRI images. The increased NUV of
TRAMP mice at 20 weeks was not remarkable (1.6-fold),
but it was significant at 24 weeks when TRAMP tumor
growth was larger (1.8±0.2-fold, P=0.004). Additional
images of the orthotopic and TRAMP models are shown in
ESM Fig. 2.
Discussion
One important observation in our studies is the increased
lipid oxidation capacity of prostate cancer cells, especially
when compared with benign cells. This enhanced lipid
oxidation is coupled with a decreased avidity for glucose
uptake, but the mechanisms underlying this association are
still debatable. Glucose transporters are not very abundant in
PCa tumors, and LNCaP cells are able to grow at control
rates even in the presence of 0.05 g/l of glucose [23], which
may account for the low [18F]FDG avidity of prostate
cancer. These observations suggest that PCa likely obtains
additional energy from fatty acid oxidation pathways,
sparing glucose use [3, 24, 25]. Furthermore, accumulating
evidence suggests that other cancers also utilize fat oxidation
as an important source of energy [26–28], highlighting the
role of fat oxidation in overall cancer growth and survival
and providing a potential link to the observation of fatty acid
metabolism and PCa risk [29, 30].
Fig. 2 Knockdown of CPT1A results in decreased lipid
oxidation and increased glucose uptake. a) Western blot of
lysates of LNCaP CPT1A KD clones (#36279 and 36281)
exposed to etomoxir for 24 h. C=control clone, V=vehicle-
treated, E=etomoxir-treated. b) [14C]Palmitic acid oxidation
rate of the control and CPT1A-KD clones, ANOVA PG0.001.
Post hoc tests, *P≤0.01 compared with control clone, ^P≤
0.004 compared with vehicle treatment. c) Normalized 2-[3H]
DG uptake in the LNCaP CPT1A KD clones, ANOVA
PG0.001. Post hoc tests, *P≤0.001, compared with vehicle
treatment, ^P≤0.001 compared with control clone.
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This study highlights the importance of lipid catabolism
in PCa cells, with potential implications for imaging of
metastatic PCa. The complete ([14C]CO2) lipid oxidation
results suggest that PCa cells are not only lipogenic [31] but
also depend on mitochondrial lipid oxidation for energy. The
results can partially be explained by abundant expression of
the CPT1A enzyme in PCa cells compared with the BPH-1
cells. The association between beta oxidation and PCa
cellular migration and invasion has been recently reported
[32], pointing to beta-oxidation as a source of energy to
sustain malignant growth.
Etomoxir is the most characterized CPT1 inhibitor [33]
that forces cells to use glucose in order to maintain energy
homeostasis. Thus, we also examined the effects of
decreased CPT1A expression on the lipid oxidation capacity
of LNCaP cells. As expected, we observed decreased fat
oxidation with decreased CPT1A expression and a concom-
itant increase in glucose uptake, suggesting that CPT1A is
mechanistically involved in the fuel switch between glucose
and fat use by PCa cells. Furthermore, a significant
unexpected upregulation of CPT1A expression was ob-
served in LNCaP cells after treatment with etomoxir
(Fig. 2b). We do not know the reason for this increase in
protein expression, but it could be due to off-target effects of
etomoxir that aim to increase fat oxidation, an effect that has
been previously described in renal failure scenarios [34].
Nevertheless, this compensatory increase in CPT1A protein
is likely inactive, since C-14-labeled lipid oxidation was
significantly reduced with etomoxir.
The tracer studies with labeled C-13 glucose also
confirmed the metabolic fate of the glucose uptake in PCa
cells, as the increased [13C]lactate exported into the medium
could only originate from the 13C-glucose added to the cells.
Thus, the weak glycolytic potential of the prostate tumors
can be enhanced by temporarily blocking their capacity to
oxidize lipids.
The increased glycolysis observed with etomoxir was
accompanied by increases in key glucose metabolism
signaling molecules like the nutrient sensor mTOR and its
downstream effector S6-kinase [35]. Activation of mTOR
and S6 kinase have also been observed in mouse hearts with
diminished fatty acid oxidation and compensatory catabo-
lism of glucose [36], suggesting a reciprocal association
between fat oxidation and aerobic glycolysis. Furthermore,
this association between mTOR and glucose uptake has also
been observed in lung cancer cells, specifically with uptake
of [18F]FDG [37].
Hexokinase 2 (HK2), the enzyme that plays the pivotal
role in the Warburg effect, was clearly increased in
xenografts of mice treated with etomoxir. HK2 generates
high levels of glucose-6-phosphate and initiates the glyco-
lytic pathway, leading to lactic acid production. The
technique of PET imaging is based on the activity of HK2,
Fig. 3 Pharmacological block in fat oxidation results in
glucose uptake in PCa cells. a) Normalized 2-[3H]DG uptake
in patient-matched prostate-derived primary cells. Student’s
ttest: *vehicle-cancer compared with vehicle-benign P=
0.044. a P=0.011 compared with benign-vehicle. #P=0.009
compared with vehicle-cancer. b) Effect of 150 μM etomoxir
on the 2-[3H]DG uptake of prostate-derived cell lines over
48 h. Bracket points to PCa cells. *Etomoxir effect at 24 h
between cells lines, ANOVA PG0.001. Post hoc tests: BPH-1
vs. LNCaP (P=0.001), PC3 (PG0.001), VCaP (P=0.017),
WPMY-1 (P=0.03). Benign WPMY-1 vs. PC3 (P=0.043).
**Etomoxir effect at 48 h between cell lines, ANOVA P=
0.005. Post hoc tests: BPH-1 vs. LNCaP (P=0.011), PC3 (P=
0.007).
Table 1. Extracellular concentrations of C-13 labeled glucose and lactate from 1-[13C]glucose in VCaP cell media as calculated from C-13 NMR spectra
Vehicle-treated cells (μM)
Mean ±SD
Lactate exported 1.02 0.05
Glucose uptake 4.77 0.56
Glucose (extracellular) 10.39 0.73
Etomoxir-treated cells (μM)
Mean ±SD P value compared with vehicle
Lactate exported 2.27 0.10 G0.001
Glucose uptake 6.46 0.71 G0.005
Glucose (extracellular) 8.57 0.69 G0.01
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as it phosphorylates and traps the [18F]FDG inside the cells,
an effect that is proportional to the tissue’s avidity for
glucose [38].
To validate our in vitro work with etomoxir, we used
three mouse models of PCa to safely enhance [18F]FDG
uptake by the tumors using a single dose of etomoxir
systemically. Recently, enhancement of [18F]FDG-PET in
PC3 xenografts has also been reported using the
antilypolytic drug acipimox, which decreases the systemic
delivery of fatty acids from the adipose tissue depots [39].
The use of drugs that target CPT1 or the entry of fatty acids
into the mitochondria (like etomoxir) may offer an added
sensitivity, since acipimox was not effective in the more
differentiated, androgen-dependent CWR22Rv1 xenografts.
Fig. 4 [18F]FDG uptake is enhanced in VCaP xenografts after systemic treatment with etomoxir. a) Representative axial (left)
and coronal images of a subcutaneous xenograft mouse model before (basal, top) and after etomoxir injection (bottom). Right
tumor is indicated with white arrow. Note the increased uptake of [18F]FDG in the heart with etomoxir treatment. This systemic
effect was observed in all the mouse models. The scale bar represents signal activity as a function of radioactivity. b)
Normalized uptake values (NUV) fold change for xenografts examined by FDG-PET, *P=0.035ttest between etomoxir and
water-treated tumors. c) Representative western blot of VCaP tumor lysates from mice treated with vehicle (water 1, 2) or
etomoxir 20 mg/kg (3–8) systemically for 24 h. d) Radioactive counts from [14C]palmitate oxidation in VCaP tumor homogenates
incubated ex vivo with water or etomoxir (150 μM) for 45 min.
Table 2. Tumor-to-tissue total activity ratios in subcutaneous mouse model
Tumor/prostate ratio (mean±SD) Tumor/muscle ratio (mean±SD) Tumor/ BAT ratio
(mean±SD)
Tumor/heart ratio (mean±SD)
Pre 24-h Pre 24-h Pre 24-h Pre 24-h
Etomoxir
(n=13)
9.06 (±6.15) 12.8a (±6.68) 0.68 (±0.45) 0.85a (±0.42) 0.55 (±0.35) 0.51 (±0.25) 0.64 (±0.62) 0.57 (±0.63)
Vehicle
(n=3)
12.67 (±4.57) 11.75 (±3.37) 0.78 (±0.36) 0.76 (±0.35) 0.56 (±0.29) 0.58 (±0.28) 0.91 (±0.49) 1.06 (±0.55)
aSignificantly different from the basal (Pre) activity ratio (P≤0.03, two-sided paired t test)
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Fig. 5 [18F]FDG uptake is enhanced in PC3-LUC orthotopic xenografts and TRAMP mouse models after systemic treatment
with etomoxir. a) Coronal (left) and sagittal PET images of representative PC3-LUC orthotopic xenografts. Bioluminescence
image on the right indicates where the tumor cells were growing; red and blue indicate high and low luciferase expression,
respectively. In the left panels (coronal views), the arrows point to the primary tumor above the bladder (strong, circular white
signal). In the right panels (sagittal views), arrows point to the ventral metastasis below the heart. This metastasis corresponds
to upper-small signal in the adjacent bioluminescence image. b) Axial (left) and sagittal PET images of representative 24-week-
old TRAMP mouse. Magnetic resonance images (sagittal and coronal) were used to anatomically visualize the increased
prostate cancer growth, which extended into the seminal vesicles. White arrows point to tumor growth located posterior to the
bladder. Bladder cannot be seen in the sagittal views, but it is visible (strong, circular white signal) in the axial views. MRI
photographs: B (bladder), P (prostate), SV (seminal vesicles), T (testis).
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The VCaP cells used in our studies are slow-growing,
androgen-sensitive, and possess a wild-type androgen
receptor [40, 41], making them a bit closer to the nature of
the indolent and [18F]FDG-PET “invisible” prostate
carcinomas.
Additionally, glucose uptake results from our primary
cancer cells also support a role for CPT1 inhibitors in
enhancing the imaging of localized human tumors. Howev-
er, interference of the prostate signal due to bladder
proximity was problematic in the TRAMP mice. Another
limitation was the increased systemic overall activity due to
the overall enhancement of tracer uptake (especially in
muscle, heart, and brown adipose tissue). Although muscle
tissue uptake was also increased with treatment, a modest
increase in the tumor/muscle ratio was observed, suggesting
that overall muscle enhancement may still allow for tumor
visualization in muscle. Importantly, there was no etomoxir-
mediated increase in [18F]FDG uptake in the healthy
prostate. We observed a significant increase in tumor/
prostate activity ratio in the etomoxir-treated mice,
underscoring the potential for FDG enhancement of local
prostate tumors by systemically manipulating lipid use in
tissues. However, given the increase in [18F]FDG uptake in
heart and brown adipose tissue, metastasis in these tissues
would not be observed (which have no clinical relevance
since these organs do not represent the major sites for
metastatic spread). Human studies will be needed to verify if
the increased glucose tracer uptake also happens in the
prostate gland and tumors.
Despite these drawbacks, [18F]FDG -PET/CT in humans
is still valuable in PCa imaging. This is the case for high-
grade localized disease and following known-osseous
disease, as in castration-resistant PCa [42] and high post-
therapeutic PSA relapse [43]. How fat-burning inhibitors
like etomoxir could modify the uptake of other lipid-
assoc ia t ed PET t r ace r s l ike [ 1 1C]ace ta t e and
[18F]fluorocholine remains to be tested.
Conclusions
Altogether, these results suggest that lipid oxidation plays a
major role in glucose and lipid homeostasis in PCa cells,
with potential for imaging enhancement that can also be
extended to other cancers as well as distant or unexpected
lesions. Although etomoxir has been used clinically, it is not
FDA-approved. Our metabolic findings open the door to
rational clinical designs to explore metabolite-based PET
imaging for prostate cancer. Other fat oxidation-related
drugs that are clinically approved for heart failure
(ranolazine, trimetazidine) may offer new imaging avenues
to be tested.
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